The Immune Microenvironment of Pancreatic Cancer
|SPEAKER:||Dana Adel Mustafa, PhD, Assistant Professor & Group Leader, Dept. Pathology & Surgery, Erasmus Medical Center|
Jan 28, 2020
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive disease associated with poor outcome. It is expected to be the leading cause of cancer-related death in 2030. The unique microenvironment of pancreatic cancer may contribute to therapy resistance. It contains an increased level of fibroblast and desmoplastic tissue, and considered as a highly immunosuppressive microenvironment.
Most PDAC patients die within the first two years, and only a small subgroup of patients exceeds this survival rate. So far, the immune-related genes and pathways long-term survivorship in PDAC are unknown. In this webinar, Dr. Mustafa presents the first comprehensive study that compares the expression and the spatial infiltration of immune cells in PDAC patients with different survival rates. The study demonstrates the use of the GeoMx™ Digital Spatial Profiler (DSP) to determine the spatial location of specific immune cells.
For Research Use Only. Not intended for use in Diagnostic Procedures.